Unintended positive and negative effects of drugs on lipoproteins

Current Opinion in Lipidology

Volumn 26, Issue 4, 2015, Pages 325-337

  Siahmansur, Tarza J ^a   Schofield, Jonathan D ^a,b   Azmi, Shazli ^a   Liu, Yifen ^a   Durrington, Paul N ^a   Soran, Handrean ^a,b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b MANCHESTER UNIVERSITY NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Cardiovascular risk; circulating lipoproteins; drugs; lipoprotein metabolism; unintended positive and negative effects

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; ANTIARRHYTHMIC AGENT; ANTIBIOTIC AGENT; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANTIDIABETIC AGENT; ANTIRETROVIRUS AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIOVASCULAR AGENT; CYCLOSPORIN; DIURETIC AGENT; DRUG; ESTROGEN; ESTROGEN RECEPTOR ANTAGONIST; GESTAGEN; GLUCOCORTICOID; GROWTH HORMONE; HORMONES AND AGENTS ACTING ON THE ENDOCRINE SYSTEM; LIPID; LIPOPROTEIN; NEUROLEPTIC AGENT; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; TESTOSTERONE; THYROID HORMONE; TRICYCLIC ANTIDEPRESSANT AGENT; VITAMIN; CENTRAL NERVOUS SYSTEM AGENTS;

ADVERSE OUTCOME; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DISEASE COURSE; DRUG EFFECT; DRUG MONITORING; DYSLIPIDEMIA; HIGH RISK PATIENT; HUMAN; LIPOPROTEIN METABOLISM; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TREATMENT DURATION; ADVERSE DRUG REACTION; ANIMAL; DRUG EFFECTS; ENDOCRINE SYSTEM; METABOLISM;

ANIMALS; CARDIOVASCULAR AGENTS; CENTRAL NERVOUS SYSTEM AGENTS; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; ENDOCRINE SYSTEM; HUMANS; LIPOPROTEINS;

EID: 84941347132     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0000000000000198     Document Type: Review

References (233)

1. Vander HeijDen M, DonDers SH, Cleophas TJ, et al. A randomized, placebocontrolled study of loop diuretics in patients with essential hypertension: the bumetaniDe and furosemiDe on lipid profile (BUFUL) clinical study report. J Clin Pharmacol 1998; 38:630-635.
2. Campbell N, Brant R, Stalts H, et al. Fluctuations in blood lipid levels during furosemiDe therapy: a randomized, double-blind, placebo-controlled crossover study. Arch Intern Med 1998; 158:1461-1463.
3. Lind L, Berne C, Pollare T, Lithell H. Metabolic effects of antihypertensive treatment with nifedipine or furosemiDe: a double-blind, cross-over study. J Hum Hypertens 1995; 9:137-141.
4. Lakshman MR, Reda DJ, Materson BJ, et al. Diuretics and beta-blockers do not have adverse effects at 1 year on plasma lipid and lipoprotein profiles in men with hypertension. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Arch Intern Med 1999; 159:551-558.
5. Grimm RH Jr, Flack JM, Grandits GA, et al. Long-term effects on plasma lipids of diet and drugs to treat hypertension. Treatment of Mild Hypertension Study (TOMHS) Research Group. JAMA 1996; 275:1549-1556.
6. Eriksson M, Zethelius B, Eeg-Olofsson K, et al. Blood lipids in 75 048 type 2 diabetic patients: a population-based survey from the Swedish National Diabetes Register. Eur J Cardiovasc Prevent Rehabilitation 2011; 18:97-105.
7. Strickland D, Sprafka JM, Luepker RV, Grimm RH Jr. Association of antihypertensive agents and blood lipids in a population-based survey. EpiDemiology 1994; 5:96-101.
8. Helmert U, Shea S. Antihypertensive treatment and serum cholesterol: results of population-based surveys in the German Cardiovascular Prevention Study. Rev Environ Health 1997; 12:253-260.
9. Hense HW, Doring A, Stieber J, Keil U. The association of antihypertensive treatment patterns and adverse lipid effects in population-based studies. J Clin EpiDemiol 1992; 45:1423-1430.
10. Kasiske BL, Ma JZ, Kalil RS, Louis TA. Effects of antihypertensive therapy on serum lipids. Ann Intern Med 1995; 122:133-141.
11. Gluck Z, Weidmann P, Mordasini R, et al. Increased serum low-Density lipoprotein cholesterol in men treated short-term with the diuretic chlorthalidone. Metab Clin Exp 1980; 29:240-245.
12. Van Brummelen P, Gevers Leuven JA, Van Gent CM. Influence of hydrochlorothiaziDe on the plasma levels of triglyceriDes, total cholesterol and HDL-cholesterol in patients with essential hypertension. Curr Med Res Opin 1979; 6:24-29.
13. Rosenthal T, Holtzman E, Segal P. The effect of chlorthalidone on serum lipids and lipoproteins. Atherosclerosis 1980; 36:111-115.
14. Lasser NL, Grandits G, Caggiula AW, et al. Effects of antihypertensive therapy on plasma lipids and lipoproteins in the Multiple Risk Factor Intervention Trial. Am J Med 1984; 76:52-66.
15. Grimm RH Jr, Leon AS, Hunninghake DB, et al. Effects of thiaziDe diuretics on plasma lipids and lipoproteins in mildly hypertensive patients: a double-blind controlled trial. Ann Intern Med 1981; 94:7-11.
16. Weidmann P, Meier A, Mordasini R, et al. Diuretic treatment and serum lipoproteins: effects of tienilic acid and indapamiDe. Klin Wochenschr 1981; 59:343-346.
17. BloomgarDen ZT, Ginsberg-Fellner F, Rayfield EJ, et al. Elevated hemoglobin A1c and low-Density lipoprotein cholesterol levels in thiaziDe-treated diabetic patients. Am J Med 1984; 77:823-827.
18. Goldman AI, Steele BW, Schnaper HW, et al. Serum lipoprotein levels during chlorthalidone therapy. A Veterans Administration-National Heart, Lung, and Blood Institute cooperative study on antihypertensive therapy: mild hypertension. JAMA 1980; 244:1691-1695.
19. Williams WR, SchneiDer KA, Borhani NO, et al. The relationship between diuretics and serum cholesterol in Hypertension Detection and Follow-up Program participants. Am J Prev Med 1986; 2:248-255.
20. Eriksson JW, Jansson PA, Carlberg B, et al. HydrochlorothiaziDe, but not CanDesartan, aggravates insulin resistance and causes visceral and hepatic fat accumulation: the mechanisms for the diabetes preventing effect of CanDesartan (MEDICA) Study. Hypertension 2008; 52:1030-1037.
21. Hobbs FR, Khan T, Collins B. Doxazosin versus bendrofluaziDe: a comparison of the metabolic effects in British South Asians with hypertension. Br J Gen Pract 2005; 55:437-443.
22. Campbell NR, Wickert WA, Shumak SL. FrusemiDe causes acute increases in lipid concentrations. Br J Clin Pharmacol 1993; 36:607-609.
23. Dodion L, Ambroes Y, Lameire N. A comparison of the pharmacokinetics and diuretic effects of two loop diuretics, torasemiDe and furosemiDe, in normal volunteers. Eur J Clin Pharmacol 1986; 31 (Suppl):21-27.
24. Jeunemaitre X, Charru A, Chatellier G, et al. Long-term metabolic effects of spironolactone and thiaziDes combined with potassium-sparing agents for treatment of essential hypertension. Am J Cardiol 1988; 62: 1072-1077.
25. Falch DK, Schreiner A. The effect of spironolactone on lipid, glucose and uric acid levels in blood during long-term administration to hypertensives. Acta Med Scand 1983; 213:27-30.
26. Eliasson K, Lins LE, Rossner S. Serum lipoprotein changes during atenolol treatment of essential hypertension. Eur J Clin Pharmacol 1981; 20:335-338.
27. Day JL, Metcalfe J, Simpson CN. Adrenergic mechanisms in control of plasma lipid concentrations. Br Med J 1982; 284:1145-1148.
28. England JD, Simons LA, Gibson JC, Carlton M. The effect of metoprolol and atenolol on plasma high Density lipoprotein levels in man. Clin Exp Pharmacol Physiol 1980; 7:329-333.
29. Simons LA, England JD, Balasubramaniam S, Viles L. Long-term treatment with slow release oxprenolol alone, or in combination with other drugs: effects on blood pressure, lipoproteins and exercise performance. Aust N Z J Med 1982; 12:612-616.
30. Johnson BF, Romero L, Johnson J, Marwaha R. Comparative effects of propranolol and prazosin upon serum lipids in thiaziDe-treated hypertensive patients. Am J Med 1984; 76:109-112.
31. Day JL, Simpson N, Metcalfe J, Page RL. Metabolic consequences of atenolol and propranolol in treatment of essential hypertension. Br Med J 1979; 1:77-80.
32. Lehtonen A, Viikari J. Long-term effect of sotalol on plasma lipids. Clin Sci 1979; 57 (Suppl 5):405s-407s.
33. MidDeke M, Weisweiler P, Schwandt P, Holzgreve H. Serum lipoproteins during antihypertensive therapy with beta blockers and diuretics: a controlled long-term comparative trial. Clin Cardiol 1987; 10:94-98.
34. Fogari R, Zoppi A, Corradi L, et al. Beta-blocker effects on plasma lipids during prolonged treatment of hypertensive patients with hypercholesterolemia. J Cardiovasc Pharmacol 1999; 33:534-539.
35. Weidmann P, Ferrier C, Saxenhofer H, et al. Serum lipoproteins during treatment with antihypertensive drugs. Drugs 1988; 35 (Suppl 6): 118-134.
36. Lehtonen A. The effect of acebutolol on plasma lipids, blood glucose and serum insulin levels. Acta Med Scand 1984; 216:57-60.
37. Lehtonen A. Long-term effect of pindolol on plasma lipids, apoproteins A, blood glucose, and serum insulin levels. Int J Clin Pharmacol Ther Toxicol 1984; 22:269-272.
38. Pollare T, Lithell H, Selinus I, Berne C. Sensitivity to insulin during treatment with atenolol and metoprolol: a randomised, double blind study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. BMJ 1989; 298:1152-1157.
39. Glanz M, Garber AJ, Mancia G, Levenstein M. Meta-analysis of studies using selective alpha1-blockers in patients with hypertension and type 2 diabetes. Int J Clin Pract 2001; 55:694-701.
40. Pessina AC, Ciccariello L, Perrone F, et al. Clinical efficacy and tolerability of alpha-blocker doxazosin as add-on therapy in patients with hypertension and impaired glucose metabolism. Nutr Metab Cardiovasc Dis 2006; 16:137-147.
41. Levy D, Walmsley P, Levenstein M. Principal results of the hypertension and lipid trial (HALT): a multicenter study of doxazosin in patients with hypertension. Am Heart J 1996; 131:966-973.
42. Pool JL. Combination antihypertensive therapy with terazosin and other antihypertensive agents: results of clinical trials. Am Heart J 1991; 122:926-931.
43. BoDen WE, Moss AJ, Oakes D. HypolipiDemic effect of type Ia antiarrhythmic agents in postinfarction patients. Circulation 1992; 85:2039-2044.
44. Sonnenblick M, Gottlieb S, Goldstein R, Abraham AS. Effect of amiodarone on blood lipids. Cardiology 1986; 73:147-150.
45. Akaike M, Azuma H, Kagawa A, et al. Effect of aspirin treatment on serum concentrations of lipoprotein(a) in patients with atherosclerotic diseases. Clin Chem 2002; 48:1454-1459.
46. Hundal RS, Petersen KF, Mayerson AB, et al. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Investig 2002; 109:1321-1326.
47. Ranga GS, Kalra OP, Tandon H, et al. Effect of aspirin on lipoprotein(a) in patients with ischemic stroke. J Stroke Cerebrovasc Dis 2007; 16:220-224.
48. Magee G, Sharpe PC. Paradoxical Decreases in high-Density lipoprotein cholesterol with fenofibrate: a quite common phenomenon. J Clin Pathol 2009; 62:250-253.
49. Schofield JD, Liu Y, France MW, et al. A review of paradoxical HDL-C responses to fenofibrate, illustrated by a case report. J Clin Lipidol 2014; 8:455-459.
50. Linz PE, Lovato LC, Byington RP, et al. Paradoxical reduction in HDL-C with fenofibrate and thiazolidinedione therapy in type 2 diabetes: the ACCORD Lipid Trial. Diabetes Care 2014; 37:686-693.
51. Serretti A, ManDelli L. AntiDepressants and body weight: a comprehensive review and meta-analysis. J Clin Psychiatry 2010; 71:1259-1272.
52. Wirshing DA, Boyd JA, Meng LR, et al. The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry 2002; 63:856-865.
53. Hummel J, Westphal S, Weber-Hamann B, et al. Serum lipoproteins improve after successful pharmacologic antiDepressant treatment: a randomized open-label prospective trial. J Clin Psychiatry 2011; 72:885-891.
54. Yeragani VK, Balon R, Pohl R, Ramesh C. Imipramine treatment and increased serum cholesterol levels. Canadian journal of psychiatry. Rev Canad Psychiatrie 1989; 34:845.
55. Kopf D, Westphal S, Luley CW, et al. Lipid metabolism and insulin resistance in Depressed patients: significance of weight, hypercortisolism, and antiDepressant treatment. J Clin Psychopharmacol 2004; 24:527-531.
56. Roessner V, Demling J, Bleich S. Doxepin increases serum cholesterol levels. Canadian journal of psychiatry. Rev Canad Psychiatrie 2004; 49:74-75.
57. Pollock BG, Perel JM, Paradis CF, et al. Metabolic and physiologic consequences of nortriptyline treatment in the elDerly. Psychopharmacol Bull 1994; 30:145-150.
58. RaeDer MB, Ferno J, Vik-Mo AO, Steen VM. SREBP activation by antipsychotic-and antiDepressant-drugs in cultured human liver cells: releVance for metabolic siDe-effects? Mol Cell Biochem 2006; 289:167-173.
59. Bailey DL, Le Melledo JM. Effects of selective serotonin reuptake inhibitors on cholesterol levels in patients with panic disorDer. J Clin Psychopharmacol 2003; 23:317-319.
60. Lara N, Archer SL, Baker GB, Le Melledo JM. Paroxetine-induced increase in metabolic end products of nitric oxiDe. J Clin Psychopharmacol 2003; 23:641-645.
61. Lara N, Baker GB, Archer SL, Le Melledo JM. Increased cholesterol levels during paroxetine administration in healthy men. J Clin Psychiatry 2003; 64:1455-1459.
62. Bilici M, Efe H, Koroglu MA, et al. Antioxidative enzyme activities and lipid peroxidation in major Depression: alterations by antiDepressant treatments. J Affect Disord 2001; 64:43-51.
63. Gulseren L, Gulseren S, Hekimsoy Z, Mete L. Comparison of fluoxetine and paroxetine in type II diabetes mellitus patients. Arch Med Res 2005; 36:159-165.
64. De Zwaan M, Nutzinger DO. Effect of fluvoxamine on total serum cholesterol levels during weight reduction. J Clin Psychiatry 1996; 57:346-348.
65. Visser M, SeiDell JC, Koppeschaar HP, Smits P. No specific effect of fluoxetine treatment on fasting glucose, insulin, lipid levels, and blood pressure in healthy men with abdominal obesity. Obes Res 1994; 2:152-159.
66. Nicholas LM, Ford AL, Esposito SM, et al. The effects of mirtazapine on plasma lipid profiles in healthy subjects. J Clin Psychiatry 2003; 64:883-889.
67. Laimer M, Kramer-Reinstadler K, Rauchenzauner M, et al. Effect of mirtazapine treatment on body composition and metabolism. J Clin Psychiatry 2006; 67:421-424.
68. Smith T, Nicholson RA. Review of duloxetine in the management of diabetic peripheral neuropathic pain. Vasc Health Risk Manag 2007; 3:833-844.
69. HollanDer P, Gupta AK, Plodkowski R, et al. Effects of naltrexone sustainedrelease/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care 2013; 36:4022-4029.
70. Raskin J, Wang F, Pritchett YL, Goldstein DJ. Duloxetine for patients with diabetic peripheral neuropathic pain: a 6-month open-label safety study. Pain Med 2006; 7:373-385.
71. Nebert DW, Russell DW. Clinical importance of the cytochromes P450. Lancet 2002; 360:1155-1162.
72. El-Farahaty RM, El-Mitwalli A, Azzam H, et al. Atherosclerotic effects of longterm old and new antiepileptic drugs monotherapy: a cross-sectional comparative study. J Child Neurol 2015; 30:451-457.
73. Nikolaos T, Stylianos G, Chryssoula N, et al. The effect of long-term antiepileptic treatment on serum cholesterol (TC, HDL, LDL) and triglyceriDe levels in adult epileptic patients on monotherapy. Med Sci Monitor 2004; 10:MT50-MT52.
74. Manimekalai K, Visakan B, Salwe KJ, Murugesan S. Evaluation of effect of antiepileptic drugs on serum lipid profile among young adults with epilepsy in a tertiary care hospital in Pondicherry. J Clin Diagn Res 2014; 8:HC05-HC09.
75. Tonstad S, Pometta D, Erkelens DW, et al. The effect of the gastrointestinal lipase inhibitor, orlistat, on serum lipids and lipoproteins in patients with primary hyperlipidaemia. Eur J Clin Pharmacol 1994; 46:405-410.
76. Rucker D, Padwal R, Li SK, et al. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007; 335:1194-1199.
77. Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999; 281:235-242.
78. Reitsma JB, Castro Cabezas M, De Bruin TW, Erkelens DW. Relationship between improved postprandial lipemia and low-Density lipoprotein metabolism during treatment with tetrahydrolipstatin, a pancreatic lipase inhibitor. Metab Clin Exp 1994; 43:293-298.
79. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012; 35:1364-1379.
80. Bolen S, Feldman L, Vassy J, et al. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. Ann Intern Med 2007; 147:386-399.
81. Lord JM, Flight IH, Norman RJ. Metformin in polycystic ovary syndrome: systematic review and meta-analysis. BMJ 2003; 327:951-953.
82. Bailey CJ, Turner RC. Metformin. N Engl J Med 1996; 334:574-579.
83. Wulffele MG, Kooy A, De Zeeuw D, et al. The effect of metformin on blood pressure, plasma cholesterol and triglyceriDes in type 2 diabetes mellitus: a systematic review. J Intern Med 2004; 256:1-14.
84. Hermann LS, Schersten B, Bitzen PO, et al. Therapeutic comparison of metformin and sulfonylurea, alone and in various combinations. A doubleblind controlled study. Diabetes Care 1994; 17:1100-1109.
85. Chu NV, Kong AP, Kim DD, et al. Differential effects of metformin and troglitazone on cardiovascular risk factors in patients with type 2 diabetes. Diabetes Care 2002; 25:542-549.
86. Monami M, Vitale V, Ambrosio ML, et al. Effects on lipid profile of dipeptidyl peptidase 4 inhibitors, pioglitazone, acarbose, and sulfonylureas: metaanalysis of placebo-controlled trials. Adv Ther 2012; 29:736-746.
87. Araki T, Emoto M, Konishi T, et al. GlimepiriDe increases high-Density lipoprotein cholesterol via increasing adiponectin levels in type 2 diabetes mellitus. Metabolism 2009; 58:143-148.
88. Buse JB, Tan MH, Prince MJ, Erickson PP. The effects of oral antihyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes. Diabetes Obes Metab 2004; 6:133-156.
89. Goldberg RB, Kendall DM, Deeg MA, et al. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipiDemia. Diabetes Care 2005; 28:1547-1554.
90. Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005; 366:1279-1289.
91. Betteridge DJ. Effects of pioglitazone on lipid and lipoprotein metabolism. Diabetes Obes Metab 2007; 9:640-647.
92. Bergenstal RM, Bailey CJ, Kendall DM. Type 2 diabetes: assessing the relative risks and benefits of glucose-lowering medications. Am J Med 2010; 123:374.
93. Berneis K, Rizzo M, Stettler C, et al. Comparative effects of rosiglitazone and pioglitazone on fasting and postprandial low-Density lipoprotein size and subclasses in patients with Type 2 diabetes. Expert Opin Pharmacother 2008; 9:343-349.
94. Deeg MA, Buse JB, Goldberg RB, et al. Pioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipiDemia. Diabetes Care 2007; 30:2458-2464.
95. Rizzo M, Christ ER, Rini GB, et al. The differential effects of thiazolidindiones on atherogenic dyslipiDemia in type 2 diabetes: what is the clinical significance? Expert Opin Pharmacother 2008; 9:2295-2303.
96. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007; 298:194-206.
97. Boland CL, Degeeter M, Nuzum DS, Tzefos M. Evaluating second-line treatment options for type2 diabetes: focus on secondary effects ofGLP-1 agonists and DPP-4 inhibitors. Ann Pharmacother 2013; 47:490-505.
98. Matikainen N, Manttari S, Schweizer A, et al. Vildagliptin therapy reduces postprandial intestinal triglyceriDe-rich lipoprotein particles in patients with type 2 diabetes. Diabetologia 2006; 49:2049-2057.
99. Charbonnel B, Karasik A, Liu J, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin adDed to ongoing metformin therapy in patients with type 2 diabetes inaDequately controlled with metformin alone. Diabetes Care 2006; 29:2638-2643.
100. Scott R, Loeys T, Davies MJ, et al. Efficacy and safety of sitagliptin when adDed to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2008; 10:959-969.
101. Wainstein J, Katz L, Engel SS, Xu L, et al. Initial therapy with the fixed-dose combination of sitagliptin and metformin results in greater improvement in glycaemic control compared with pioglitazone monotherapy in patients with type 2 diabetes. Diabetes Obes Metab 2012; 14:409-418.
102. Lavalle-Gonzalez FJ, Januszewicz A, Davidson J, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia 2013; 56:2582-2592.
103. BlonDe L, Klein EJ, Han J, et al. Interim analysis of the effects of exenatiDe treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes. Diabetes Obes Metab 2006; 8:436-447.
104. Schwartz EA, Koska J, Mullin MP, et al. ExenatiDe suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus. Atherosclerosis 2010; 212:217-222.
105. Bergenstal RM, Wysham C, Macconell L, et al. Efficacy and safety of exenatiDe once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010; 376:431-439.
106. Ratner RE, Maggs D, Nielsen LL, et al. Long-term effects of exenatiDe therapy over 82 weeks on glycaemic control and weight in over-weight metformintreated patients with type 2 diabetes mellitus. Diabetes Obes Metab 2006; 8:419-428.
107. Vilsboll T, Zdravkovic M, Le-Thi T, et al. LiraglutiDe, a long-acting human glucagon-like peptiDe-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. Diabetes Care 2007; 30:1608-1610.
108. Bailey CJ, Gross JL, Pieters A, et al. Effect of dapagliflozin in patients with type 2 diabetes who have inaDequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 2010; 375:2223-2233.
109. Ferrannini E, Ramos SJ, Salsali A, et al. Dapagliflozin monotherapy in type 2 diabetic patients with inaDequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care 2010; 33:2217-2224.
110. Forst T, Guthrie R, GolDenberg R, et al. Efficacy and safety of canagliflozin over 52 weeks in patients with type 2 diabetes on background metformin and pioglitazone. Diabetes Obes Metab 2014; 16:467-477.
111. Neal B, Perkovic V, De Zeeuw D, et al. Rationale, Design, and baseline characteristics of the Canagliflozin Cardiovascular Assessment Study (CANVAS): a randomized placebo-controlled trial. Am Heart J 2013; 166:217-223; e11.
112. Mihailescu DV, Vora A, Mazzone T. Lipid effects of endocrine medications. Curr Atheroscler Rep 2011; 13:88-94.
113. Mazzone T, Foster D, Chait A. In vivo stimulation of low-Density lipoprotein Degradation by insulin. Diabetes 1984; 33:333-338.
114. Svenson KL, Lithell H, Hallgren R, Vessby B. Serum lipoprotein in active rheumatoid arthritis and other chronic inflammatory arthritiDes. II. Effects of anti-inflammatory and disease-modifying drug treatment. Arch Intern Med 1987; 147:1917-1920.
115. Henkin Y, Como JA, Oberman A. Secondary dyslipiDemia. Inadvertent effects of drugs in clinical practice. JAMA 1992; 267:961-968.
116. Boers M, Nurmohamed MT, Doelman CJ, et al. Influence of glucocorticoids and disease activity on total and high Density lipoprotein cholesterol in patients with rheumatoid arthritis. Ann Rheumatic Dis 2003; 62:842-845.
117. Petri M, Perez-Gutthann S, Spence D, Hochberg MC. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med 1992; 93:513-519.
118. MacGregor AJ, Dhillon VB, BinDer A, et al. Fasting lipids and anticardiolipin antibodies as risk factors for vascular disease in systemic lupus erythematosus. Ann Rheumatic Dis 1992; 51:152-155.
119. Leong KH, Koh ET, Feng PH, Boey ML. Lipid profiles in patients with systemic lupus erythematosus. J Rheumatol 1994; 21:1264-1267.
120. Choi HK, Seeger JD. Glucocorticoid use and serum lipid levels in US adults: the Third National Health and Nutrition Examination Survey. Arthritis Rheum 2005; 53:528-535.
121. Ettinger WH, Klinefelter HF, Kwiterovitch PO. Effect of short-term, low-dose corticosteroids on plasma lipoprotein lipids. Atherosclerosis 1987; 63:167-172.
122. EbDen P, McNally P, Samanta A, Fancourt GJ. The effects of high dose inhaled beclomethasone dipropionate on glucose and lipid profiles in normal and diet controlled diabetic subjects. Resp Med 1989; 83:289-291.
123. Turpeinen M, Sorva R, Juntunen-Backman K. Changes in carbohydrate and lipid metabolism in children with asthma inhaling buDesoniDe. J Allergy Clin Immunol 1991; 88:384-389.
124. Yavuz O, Turktas I, Cevik C. The effect of high-dose inhaled buDesoniDe on lipid profile in asthmatic patients. Gen Pharmacol 1996; 27:89-90.
125. Muls E, RosseneuM, Blaton V, et al. Serum lipids and apolipoproteins A-I, A-II and B in primary hypothyroidism before and during treatment. Eur J Clin Investig 1984; 14:12-15.
126. O'Brien T, Dinneen SF, O'Brien PC, Palumbo PJ. HyperlipiDemia in patients with primary and secondary hypothyroidism. Mayo Clin Proc 1993; 68:860-866.
127. Ito M, Arishima T, Kudo T, et al. Effect of levo-thyroxine replacement on nonhigh-Density lipoprotein cholesterol in hypothyroid patients. J Clin Endocrinol Metab 2007; 92:608-611.
128. Danese MD, LaDenson PW, Meinert CL, Powe NR. Clinical review 115: effect of thyroxine therapy on serum lipoproteins in patients with mild thyroid failure: a quantitative review of the literature. J Clin Endocrinol Metab 2000; 85:2993-3001.
129. Villar HC, Saconato H, Valente O, Atallah AN. Thyroid hormone replacement for subclinical hypothyroidism. Cochrane Database Syst Rev 2007; CD003419.
130. LaDenson PW, Kristensen JD, Ridgway EC, et al. Use of the thyroid hormone analogue eprotirome in statin-treated dyslipiDemia. N Engl J Med 2010; 362:906-916.
131. Berkenstam A, Kristensen J, Mellstrom K, et al. The thyroid hormone mimetic compound KB2115 lowers plasma LDL cholesterol and stimulates bile acid synthesis without cardiac effects in humans. Proc Natl Acad Sci USA 2008; 105:663-667.
132. Cuneo RC, Salomon F, Watts GF, et al. Growth hormone treatment improves serum lipids and lipoproteins in adults with growth hormone Deficiency. Metab Clin Exp 1993; 42:1519-1523.
133. Russell-Jones DL, Watts GF, Weissberger A, et al. The effect of growth hormone replacement on serum lipids, lipoproteins, apolipoproteins and cholesterol precursors in adult growth hormone Deficient patients. Clin Endocrinol 1994; 41:345-350.
134. Johannsson G, Oscarsson J, Rosen T, et al. Effects of 1 year of growth hormone therapy on serum lipoprotein levels in growth hormone-Deficient adults. Influence of genDer and Apo(a) and ApoE phenotypes. Arterioscler Thromb Vasc Biol 1995; 15:2142-2150.
135. al-Shoumer KA, Gray R, Anyaoku V, et al. Effects of four years' treatment with biosynthetic human growth hormone (GH) on glucose homeostasis, insulin secretion and lipid metabolism in GH-Deficient adults. Clin Endocrinol 1998; 48:795-802.
136. Christ ER, Cummings MH, Albany E, et al. Effects of growth hormone (GH) replacement therapy on very low Density lipoprotein apolipoprotein B100 kinetics in patients with adult GH Deficiency: a stable isotope study. J Clin Endocrinol Metab 1999; 84:307-316.
137. Gotherstrom G, Svensson J, Koranyi J, et al. A prospective study of 5 years of GH replacement therapy in GH-Deficient adults: sustained effects on body composition, bone mass, and metabolic indices. J Clin Endocrinol Metab 2001; 86:4657-4665.
138. Barreto-Filho JA, Alcantara MR, Salvatori R, et al. Familial isolated growth hormone Deficiency is associated with increased systolic blood pressure, central obesity, and dyslipiDemia. J Clin Endocrinol Metab 2002; 87:2018-2023.
139. Hoffman AR, Kuntze JE, Baptista J, et al. Growth hormone (GH) replacement therapy in adult-onset gh Deficiency: effects on body composition in men and women in a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab 2004; 89:2048-2056.
140. Bollerslev J, Ueland T, Jorgensen AP, et al. Positive effects of a physiological dose ofGHonmarkers of atherogenesis: a placebo-controlled study in patients with adult-onset GH Deficiency. Eur J Endocrinol 2006; 154:537-543.
141. Beshyah SA, HenDerson A, Niththyananthan R, et al. The effects of short and long-term growth hormone replacement therapy in hypopituitary adults on lipid metabolism and carbohydrate tolerance. J Clin Endocrinol Metab 1995; 80:356-363.
142. Weaver JU, Monson JP, Noonan K, et al. The effect of low dose recombinant human growth hormone replacement on regional fat distribution, insulin sensitivity, and cardiovascular risk factors in hypopituitary adults. J Clin Endocrinol Metab 1995; 80:153-159.
143. Beauregard C, Utz AL, Schaub AE, et al. Growth hormone Decreases visceral fat and improves cardiovascular risk markers in women with hypopituitarism: a randomized, placebo-controlled study. J Clin Endocrinol Metab 2008; 93:2063-2071.
144. Miller KK, Wexler T, Fazeli P, et al. Growth hormone Deficiency after treatment of acromegaly: a randomized, placebo-controlled study of growth hormone replacement. J Clin Endocrinol Metab 2010; 95:567-577.
145. Leese GP, Wallymahmed M, VanHeyningen C, et al. HDL-cholesterol reductions associated with adult growth hormone replacement. Clin Endocrinol 1998; 49:673-677.
146. Sesmilo G, Biller BM, Llevadot J, et al. Effects of growth hormone administration on inflammatory and other cardiovascular risk markers in men with growth hormone Deficiency. A randomized, controlled clinical trial. Ann Intern Med 2000; 133:111-122.
147. O'Halloran DJ, Wieringa G, Tsatsoulis A, Shalet SM. Increased serum lipoprotein(a) concentrations after growth hormone (GH) treatment in patients with isolated GH Deficiency. Ann Clin Biochem 1996; 33:330-334.
148. Haffner SM, Mykkanen L, ValDez RA, Katz MS. Relationship of sex hormones to lipids and lipoproteins in nondiabetic men. J Clin Endocrinol Metab 1993; 77:1610-1615.
149. Makinen JI, Perheentupa A, Irjala K, et al. Endogenous testosterone and serum lipids in middle-aged men. Atherosclerosis 2008; 197:688-693.
150. Haring R, Volzke H, Steveling A, et al. Low serum testosterone levels are associated with increased risk of mortality in a population-based cohort of men aged 20-79. Eur Heart J 2010; 31:1494-1501.
151. Akishita M, Fukai S, Hashimoto M, et al. Association of low testosterone with metabolic syndrome and its components in middle-aged Japanese men. Hypertens Res 2010; 33:587-591.
152. FernanDez-Balsells MM, Murad MH, Lane M, et al. Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and metaanalysis. J Clin Endocrinol Metab 2010; 95:2560-2575.
153. Firtser S, Juonala M, Magnussen CG, et al. Relation of total and free testosterone and sex hormone-binding globulin with cardiovascular risk factors in men aged 24-45 years. The Cardiovascular Risk in Young Finns Study. Atherosclerosis 2012; 222:257-262.
154. Monroe AK, Dobs AS. The effect of androgens on lipids. Curr Opin Endocrinol Diabetes Obes 2013; 20:132-139.
155. Haring R, Teng Z, Xanthakis V, et al. Association of sex steroids, gonadotrophins, and their trajectories with clinical cardiovascular disease and allcause mortality in elDerly men from the Framingham Heart Study. Clin Endocrinol 2013; 78:629-634.
156. Zhao J, Jiang C, Lam TH, et al. Genetically predicted testosterone and cardiovascular risk factors in men: a MenDelian randomization analysis in the Guangzhou Biobank Cohort Study. Int J EpiDemiol 2014; 43: 140-148.
157. Thompson PD, Cullinane EM, Sady SP, et al. Contrasting effects of testosterone and stanozolol on serum lipoprotein levels. JAMA 1989; 261:1165-1168.
158. Zgliczynski S, Ossowski M, Slowinska-Srzednicka J, et al. Effect of testosterone replacement therapy on lipids and lipoproteins in hypogonadal and elDerly men. Atherosclerosis 1996; 121:35-43.
159. Zitzmann M. Mechanisms of disease: pharmacogenetics of testosterone therapy in hypogonadal men. Nat Clin Pract Urol 2007; 4:161-166.
160. Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med 2010; 363:109-122.
161. Somboonporn W, Davis S, Seif MW, Bell R. Testosterone for peri-and postmenopausal women. Cochrane Database Syst Rev 2005; CD004509.
162. Wierckx K, Van Caenegem E, Schreiner T, et al. Cross-sex hormone therapy in trans persons is safe and effective at short-time follow-up: results from the European network for the investigation of genDer incongruence. J Sexual Med 2014; 11:1999-2011.
163. Smith JC, Bennett S, EVans LM, et al. The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab 2001; 86:4261-4267.
164. Dockery F, Bulpitt CJ, Agarwal S, et al. Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci 2003; 104:195-201.
165. Smith MR, Lee H, Nathan DM. Insulin sensitivity during combined androgen blockaDe for prostate cancer. J Clin Endocrinol Metab 2006; 91:1305-1308.
166. Harrington JM, Schwenke DC, Epstein DR, Bailey DE Jr. Androgen-Deprivation therapy and metabolic syndrome in men with prostate cancer. Oncol Nursing Forum 2014; 41:21-29.
167. Saylor PJ, Smith MR. Metabolic complications of androgen Deprivation therapy for prostate cancer. J Urol 2013; 189 (1 Suppl):S34-S42.
168. Yannucci J, Manola J, Garnick MB, et al. The effect of androgen Deprivation therapy on fasting serum lipid and glucose parameters. J Urol 2006; 176:520-525.
169. Rijpkema AH, Vander SanDen AA, Ruijs AH. Effects of postmenopausal oestrogen-progestogen replacement therapy on serum lipids and lipoproteins: a review. Maturitas 1990; 12:259-285.
170. Miller VT, Muesing RA, LaRosa JC, et al. Effects of conjugated equine estrogen with and without three different progestogens on lipoproteins, high-Density lipoprotein subfractions, and apolipoprotein A-I. Obstetr Gynecol 1991; 77:235-240.
171. Walsh BW, Schiff I, Rosner B, et al. Effects of postmenopausal estrogen replacement on the concentrations and metabolism of plasma lipoproteins. N Engl J Med 1991; 325:1196-1204.
172. Lobo RA, Pickar JH, Wild RA, et al. Metabolic impact of adding medroxyprogesterone acetate to conjugated estrogen therapy in postmenopausal women. The Menopause Study Group. Obstetr Gynecol 1994; 84:987-995.
173. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. JAMA 1995; 273:199-208.
174. McManus J, McEneny J, Young IS, Thompson W. The effect of various oestrogens and progestogens on the susceptibility of low Density lipoproteins to oxidation in vitro. Maturitas 1996; 25:125-131.
175. BinDer EF, Williams DB, Schechtman KB, et al. Effects of hormone replacement therapy on serum lipids in elDerly women: a randomized, placebocontrolled trial. Ann Intern Med 2001; 134:754-760.
176. Baker VL. Alternatives to oral estrogen replacement. TransDermal patches, percutaneous gels, vaginal creams and rings, implants, other methods of Delivery. Obstetr Gynecol Clin North Am 1994; 21:271-297.
177. Chetkowski RJ, Meldrum DR, Steingold KA, et al. Biologic effects of transDermal estradiol. N Engl J Med 1986; 314:1615-1620.
178. Godsland IF, Crook D, Simpson R, et al. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med 1990; 323:1375-1381.
179. Ball MJ, Ashwell E, Jackson M, Gillmer MD. Comparison of two triphasic contraceptives with different progestogens: effects on metabolism and coagulation proteins. Contraception 1990; 41:363-376.
180. Enk L, Landgren BM, Lindberg UB, et al. A prospective, one-year study on the effects of two long acting injectable contraceptives (Depot-medroxyprogesterone acetate and norethisterone oenanthate) on serum and lipoprotein lipids. Hormone Metab Res 1992; 24:85-89.
181. McEwan JA, Griffin M, Fotherby K, Trayner I. Long-term use of Depotnorethisterone enanthate: effect on blood lipid fractions. Contraception 1992; 46:49-60.
182. Fahmy K, Khairy M, Allam G, et al. Effect of Depo-medroxyprogesterone acetate on coagulation factors and serum lipids in Egyptian women. Contraception 1991; 44:431-444.
183. Garza-Flores J, Dela Cruz DL, Valles De Bourges V, et al. Long-term effects of Depot-medroxyprogesterone acetate on lipoprotein metabolism. Contraception 1991; 44:61-71.
184. Kim CJ, Jang HC, Cho DH, Min YK. Effects of hormone replacement therapy on lipoprotein(a) and lipids in postmenopausal women. Arteriosclerosis Thrombosis 1994; 14:275-281.
185. Darling GM, Johns JA, McCloud PI, Davis SR. Estrogen and progestin compared with simvastatin for hypercholesterolemia in postmenopausal women. N Engl J Med 1997; 337:595-601.
186. LaRosa JC. Effects of oral contraceptives on circulating lipids and lipoproteins: maximizing benefit, minimizing risk. Int J Fertility 1989; 34 (Suppl): 71-84.
187. Mantel-Teeuwisse AK, Kloosterman JM, Maitland-Vander Zee AH, et al. Drug-Induced lipid changes: a review of the unintenDed effects of some commonly used drugs on serum lipid levels. Drug Safety 2001; 24:443-456.
188. Burkman RT, Robinson JC, Kruszon-Moran D, et al. Lipid and lipoprotein changes associated with oral contraceptive use: a randomized clinical trial. Obstetr Gynecol 1988; 71:33-38.
189. Burkman RT, Zacur HA, Kimball AW, et al. Oral contraceptives and lipids and lipoproteins: part I-variations in mean levels by oral contraceptive type. Contraception 1989; 40:553-561.
190. Kafrissen ME, Corson SL. Comparative review of third-generation progestins. Int J Fertility 1992; 37 (Suppl 2):104-115.
191. Speroff L, DeCherney A. Evaluation of a new generation of oral contraceptives. The Advisory Board for the New Progestins. Obstetr Gynecol 1993; 81:1034-1047.
192. Kiriwat O, Petyim S. The effects of transDermal contraception on lipid profiles, carbohydrate metabolism and coagulogram in Thai women. Gynecol Endocrinol 2010; 26:361-365.
193. Grey AB, Stapleton JP, EVans MC, et al. The effect of the antiestrogen tamoxifen on bone mineral Density in normal late postmenopausal women. Am J Med 1995; 99:636-641.
194. Benshushan A, Brzezinski A. Tamoxifen effects on menopause-associated risk factors and symptoms. Obstetr Gynecol Survey 1999; 54:272-278.
195. Hozumi Y, Kawano M, Saito T, Miyata M. Effect of tamoxifen on serum lipid metabolism. J Clin Endocrinol Metab 1998; 83:1633-1635.
196. Draper MW, Flowers DE, Huster WJ, et al. A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women. J Bone Miner Res 1996; 11:835-842.
197. Delmas PD, Bjarnason NH, Mitlak BH, et al. Effects of raloxifene on bone mineral Density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 1997; 337:1641-1647.
198. Walsh BW, Kuller LH, Wild RA, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA 1998; 279:1445-1451.
199. Lufkin EG, Whitaker MD, Nickelsen T, et al. Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial. J Bone Miner Res 1998; 13:1747-1754.
200. Estrada V, Portilla J. DyslipiDemia related to antiretroviral therapy. AIDS Rev 2011; 13:49-56.
201. Carr A, Samaras K, Burton S, et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12:F51-F58.
202. Romeu J, Balague M, Ruiz L, et al. Short-term risk for AIDS-indicator diseases predicted by plasma HIV-1 RNA and CD4\+ lymphocytes. Scand J Infect Dis 1999; 31:37-42.
203. Levy AR, McCandless L, Harrigan PR, et al. Changes in lipids over twelve months after initiating protease inhibitor therapy among persons treated for HIV/AIDS. Lipids Health Dis 2005; 4:4.
204. Danner SA, Carr A, Leonard JM, et al. A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group. N Engl J Med 1995; 333:1528-1533.
205. Markowitz M, SaagM, PowDerly WG, et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med 1995; 333:1534-1539.
206. Cameron DW, Heath-Chiozzi M, Danner S, et al. Randomised placebocontrolled trial of ritonavir in adVanced HIV-1 disease. The AdVanced HIV Disease Ritonavir Study Group. Lancet 1998; 351:543-549.
207. Samuel P, Holtzman CM, Meilman E, Sekowski I. Effect of neomycin and other antibiotics on serum cholesterol levels and on 7alpha-Dehydroxylation of bile acids by the fecal bacterial flora in man. Circ Res 1973; 33:393-402.
208. von Bergmann K, Streicher U, Leiss O, et al. Serum-cholesterol-lowering effect of metronidazole and possible mechanisms of action. Klinische Wochenschr 1985; 63:279-281.
209. Betti R, Palvarini M, Marmini A, et al. Metronidazole in hyperlipiDemic subjects. Panminerva Med 1987; 29:79-81.
210. Davis JL, Schultz TA, Mosley CA. Metronidazole lowers serum lipids. Ann Intern Med 1983; 99:43-44.
211. Ducobu J, Fontaine C. Metronidazole and serum lipids. Artery 1986; 13:264-266.
212. Jenkins DJ, Kendall CW, Hamidi M, et al. Effect of antibiotics as cholesterollowering agents. Metab Clin Exp 2005; 54:103-112.
213. Zech LA, Gross EG, Peck GL, Brewer HB. Changes in plasma cholesterol and triglyceriDe levels after treatment with oral isotretinoin. A prospective study. Arch Dermatol 1983; 119:987-993.
214. MarsDen JR, Trinick TR, Laker MF, Shuster S. Effects of isotretinoin on serum lipids and lipoproteins, liver and thyroid function. Clin Chim Acta 1984; 143:243-251.
215. Vieira AS, Beijamini V, Melchiors AC. The effect of isotretinoin on triglyceriDes and liver aminotransferases. Anais Brasileiros Dermatol 2012; 87:382-387.
216. Scarisbrick JJ, Morris S, Azurdia R, et al. U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma. Br J Dermatol 2013; 168:192-200.
217. De Vries-Vander Weij J, De Haan W, Hu L, et al. Bexarotene induces dyslipiDemia by increased very low-Density lipoprotein production and cholesteryl ester transfer protein-mediated reduction of high-Density lipoprotein. Endocrinology 2009; 150:2368-2375.
218. JorDe R, Grimnes G. Vitamin D and metabolic health with special reference to the effect of vitamin D on serum lipids. Prog Lipid Res 2011; 50:303-312.
219. Zittermann A, Frisch S, Berthold HK, et al. Vitamin D supplementation enhances the beneficial effects of weight loss on cardiovascular disease risk markers. Am J Clin Nutr 2009; 89:1321-1327.
220. Heikkinen AM, Tuppurainen MT, Niskanen L, et al. Long-term vitamin D3 supplementation may have adverse effects on serum lipids during postmenopausal hormone replacement therapy. Eur J Endocrinol 1997; 137:495-502.
221. Major GC, Alarie F, Dore J, et al. Supplementation with calcium \+ vitamin D enhances the beneficial effect of weight loss on plasma lipid and lipoprotein concentrations. Am J Clin Nutr 2007; 85:54-59.
222. Zemel MB, Shi H, Greer B, et al. Regulation of adiposity by dietary calcium. FASEB J 2000; 14:1132-1138.
223. Jacqmain M, Doucet E, Despres JP, et al. Calcium intake, body composition, and lipoprotein-lipid concentrations in adults. Am J Clin Nutr 2003; 77:1448-1452.
224. Chai W, Cooney RV, Franke AA, Bostick RM. Effects of calcium and vitamin D supplementation on blood pressure and serum lipids and carotenoids: a randomized, double-blind, placebo-controlled, clinical trial. Ann EpiDemiol 2013; 23:564-570.
225. Scragg R, Khaw K-T, Murphy S. Effect of winter oral vitamin D3 supplementation on cardiovascular risk factors in elDerly adults. Eur J Clin Nutr 1995; 49:640-646.
226. AnDersen R, Brot C, Mejborn H, et al. Vitamin D supplementation does not affect serum lipids and lipoproteins in Pakistani immigrants. Eur J Clin Nutr 2009; 63:1150-1153.
227. Pfeifer M, Begerow B, Minne HW, et al. Effects of a short-term vitamin D3 and calcium supplementation on blood pressure and parathyroid hormone levels in elDerly women 1. J Clin Endocrinol Metab 2001; 86:1633-1637.
228. von Hurst PR, Stonehouse W, Coad J. Vitamin D supplementation reduces insulin resistance in South Asian women living in New Zealand who are insulin resistant and vitamin D Deficient: a randomised, placebo-controlled trial. Br J Nutr 2010; 103:549-555.
229. Nagpal J, PanDe J, Bhartia A. A double-blind, randomized, placebo-controlled trial of the short-term effect of vitamin D3 supplementation on insulin sensitivity in apparently healthy, middle-aged, centrally obese men. Diabetic Med 2009; 26:19-27.
230. Witham M, Dove F, Sugden J, et al. The effect of vitamin D replacement on markers of vascular health in stroke patients: a randomised controlled trial. Nutr Metab Cardiovasc Dis 2012; 22:864-870.
231. JorDe R, Sneve M, Torjesen P, Figenschau Y. No improvement in cardiovascular risk factors in overweight and obese subjects after supplementation with vitamin D3 for 1 year. J Intern Med 2010; 267:462-472.
232. Rajpathak SN, Xue X, Wassertheil-Smoller S, et al. Effect of 5 y of calcium plus vitamin D supplementation on change in circulating lipids: results from the Women's Health Initiative. Am J Clin Nutr 2010; 91:894-899.
233. Kanbay M, Yildirir A, Akcay A, et al. Effects of immunosuppressive drugs on serum lipid levels in renal transplant recipients. Transplant Proc 2006; 38:502-505.